BioGend Therapeutics Co., Ltd. (TPEX:6733)

Market Cap	3.18B -41.6%
Revenue (ttm)	236.58M +21.3%
Net Income	-67.84M
EPS	-0.54
Shares Out	134.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,010
Open	23.50
Previous Close	23.80
Day's Range	23.45 - 23.85
52-Week Range	23.40 - 46.75
Beta	0.08
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 9, 2026

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was fou...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6733

Financial Performance

In 2025, BioGend Therapeutics's revenue was 222.34 million, an increase of 32.62% compared to the previous year's 167.65 million. Losses were -84.61 million, -27.36% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 20, 2026

Data Sources Report a data error